Kidney Transplant: Optimal Dose of Grafalon®

We are studying the best dose of Grafalon® for kidney transplant patients with low immunological risk. This trial aims to prevent complications and evaluate the medication's safety and effects on kidney function and infections.

>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInjectionInternal MedicineNephrology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Anti-T Lymphocyte Immunoglobulin For Human Use
Anti-T lymphocyte immunoglobulin is a preparation of antibodies that reduces activity of immune T cells to prevent or treat organ transplant rejection.
Mycophenolic Acid
Mycophenolic acid is a substance that suppresses the immune system to help prevent organ transplant rejection and control autoimmune diseases.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
CHU Besancon
Nephrology
Besançon, France
Sponsor: Centre Hospitalier Regional Universitaire
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.